
Number of publications published per year by Gish, Robert G.. (Source : PubMed)

Distribution of publications types for Gish, Robert G.. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
J. Viral Hepat.
2010;17;1

Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
J. Viral Hepat.
2009;16;11
Safety and efficacy of viramidine versus ribavirin in ViSER2: Randomized, double-blind study in therapy-naive hepatitis C patients.
J. Hepatol.
2009

To "be" or not to "be": that is the question.
Am. J. Gastroenterol.
2009;104;8
A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma.
Hepatology international
2009
Monotherapy vs multiple-drug therapy: the experts debate.
Cleve Clin J Med
2009;76 Suppl 3
Hepatitis B treatment: Current best practices, avoiding resistance.
Cleve Clin J Med
2009;76 Suppl 3
Diagnosis of chronic hepatitis B and the implications of viral variants and mutations.
Am. J. Med.
2008;121;12 Suppl

Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis.
Aliment. Pharmacol. Ther.
2008;27;12

Hepatocellular carcinoma (HCC): current and evolving therapies.
IDrugs
2008;11;3
[ See timeline ] [ See all publications ]
means that Gish, Robert G. has 35 papers cited a least 35 times - methodology
Hôpital Beaujon, Clichy, France.
Due mainly to homonyms, errors are possible and if you detect "false positives" or "false negatives" don't be too frustrated and please contact the webmaster.